Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Francisco J Bautista SirventXavier PaolettiJonathan RubinoCaroline BrardKeyvan RezaiSouad NebchiAnne Isabelle BertozziIsabelle AertsEmilie De CarliNatasha van EijkelenburgEstelle ThebaudNadège CorradiniAnne-Sophie DefachellesStephane DucassouRaphael J MorscherGilles VassalDidier FrappazPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Ribociclib in combination with TOTEM or everolimus was well-tolerated. The observed activity signals initiated a follow-up study of the ribociclib-everolimus combination in a population enriched with molecular alterations within both pathways.